FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367305422> ?p ?o ?g. }

• W4367305422 abstract "<h3>Objective:</h3> To describe the effects of COVID-19 on comorbid myasthenia gravis (MG) regarding common symptoms such as limb weakness, oculobulbar weakness, and respiratory failure by evaluating worsening MGFA scores or therapy escalation following COVID-19 infection. <h3>Background:</h3> Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fluctuating weakness that affects the limbs, oculobulbar muscles, and diaphragm. Therapies include steroids and immunosuppressants, placing patients at high risk of opportunistic infections. Certain triggers can worsen MG, such as medications and infections. We describe the outcomes of 36 patients with confirmed MG and COVID-19, with particular focus on changes in Myasthenia Gravis Foundation of America (MGFA) scores and treatment escalation following infection. <h3>Design/Methods:</h3> Single center retrospective chart review of 36 patients from March 2020-January 2022 with clinically or serologically confirmed MG and COVID-19 <h3>Results:</h3> Of these 36 patients, 20 (55.6%) were not vaccinated against COVID. Twelve patients (33%) had MGFA scores of 3 or 4. Nineteen patients (53%) were prescribed steroids and 18 patients (50%) were on alternate immunotherapy prior to diagnosis of COVID. A total of 5 patients (14%) had a change in baseline MGFA score. One patient’s MGFA score worsened from 1 to 2 and 4 patients required MG treatment escalation. <h3>Conclusions:</h3> Myasthenia gravis patients with higher premorbid MGFA scores, steroid use, or other immunosuppressive therapy would be expected to have worse clinical outcomes in their MG course following COVID infection. Our results indicate 14% of MG patients with COVID had a change from their baseline MGFA score. Our study results revealed higher premorbid MGFA scores or use of immunosuppressant therapy did not alter a patient’s MGFA score following COVID infection. These results are consistent with current literature that COVID infection has little impact on these patients. <b>Disclosure:</b> Dr. Sandhu has nothing to disclose. Dr. Quezada has nothing to disclose. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSI. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pharmawrite. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for amylyx. Dr. Rana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Small has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion." @default.
• W4367305422 created "2023-04-29" @default.
• W4367305422 creator A5010342160 @default.
• W4367305422 creator A5029664898 @default.
• W4367305422 creator A5041298861 @default.
• W4367305422 creator A5065077547 @default.
• W4367305422 date "2023-04-25" @default.
• W4367305422 modified "2023-09-26" @default.
• W4367305422 title "Effect of COVID-19 on Myasthenia Gravis (P2-8.006)" @default.
• W4367305422 doi "https://doi.org/10.1212/wnl.0000000000203343" @default.
• W4367305422 hasPublicationYear "2023" @default.
• W4367305422 type Work @default.
• W4367305422 citedByCount "0" @default.
• W4367305422 crossrefType "proceedings-article" @default.
• W4367305422 hasAuthorship W4367305422A5010342160 @default.
• W4367305422 hasAuthorship W4367305422A5029664898 @default.
• W4367305422 hasAuthorship W4367305422A5041298861 @default.
• W4367305422 hasAuthorship W4367305422A5065077547 @default.
• W4367305422 hasConcept C126322002 @default.
• W4367305422 hasConcept C141071460 @default.
• W4367305422 hasConcept C167135981 @default.
• W4367305422 hasConcept C2776418732 @default.
• W4367305422 hasConcept C2778105408 @default.
• W4367305422 hasConcept C2779134260 @default.
• W4367305422 hasConcept C2780247198 @default.
• W4367305422 hasConcept C3008058167 @default.
• W4367305422 hasConcept C524204448 @default.
• W4367305422 hasConcept C71924100 @default.
• W4367305422 hasConceptScore W4367305422C126322002 @default.
• W4367305422 hasConceptScore W4367305422C141071460 @default.
• W4367305422 hasConceptScore W4367305422C167135981 @default.
• W4367305422 hasConceptScore W4367305422C2776418732 @default.
• W4367305422 hasConceptScore W4367305422C2778105408 @default.
• W4367305422 hasConceptScore W4367305422C2779134260 @default.
• W4367305422 hasConceptScore W4367305422C2780247198 @default.
• W4367305422 hasConceptScore W4367305422C3008058167 @default.
• W4367305422 hasConceptScore W4367305422C524204448 @default.
• W4367305422 hasConceptScore W4367305422C71924100 @default.
• W4367305422 hasLocation W43673054221 @default.
• W4367305422 hasOpenAccess W4367305422 @default.
• W4367305422 hasPrimaryLocation W43673054221 @default.
• W4367305422 hasRelatedWork W2097813958 @default.
• W4367305422 hasRelatedWork W2176863503 @default.
• W4367305422 hasRelatedWork W2326116919 @default.
• W4367305422 hasRelatedWork W2352208351 @default.
• W4367305422 hasRelatedWork W2358833249 @default.
• W4367305422 hasRelatedWork W2605607543 @default.
• W4367305422 hasRelatedWork W2900764113 @default.
• W4367305422 hasRelatedWork W2966077819 @default.
• W4367305422 hasRelatedWork W3124709147 @default.
• W4367305422 hasRelatedWork W3202048764 @default.
• W4367305422 isParatext "false" @default.
• W4367305422 isRetracted "false" @default.
• W4367305422 workType "article" @default.